[FASEB Journal] Transcriptomic profiling of the human response to exercise revealed that the nuclear receptor NR4A3 (NOR-1) was among the most responsive genes to acute exercise.
[ACS Nano ] A laser-assisted electrohydrodynamic printing strategy was proposed to directly fabricate a microfibrous architecture with built-in microelectronics for electrophysiological monitoring of aligned cardiomyocytes.
[Clinical Cancer Research] In 83 large B-cell lymphoma patients, the skeletal muscle index was measured from clinical images obtained at baseline and days 30 and 90 post-therapy.
[Nature Reviews Endocrinology] The authors review established and emerging cellular mechanisms of insulin resistance, their complex integrative features and their relevance to disease progression.
[American Journal of Physiology-Gastrointestinal and Liver Physiology] As an approach to investigate the relationship between alcohol-enhanced obstructive sleep apnea and alcohol-related liver disease (ALD) development/progression in vivo Gao-binge ALD and chronic intermittent hypoxia mouse models were established.
[Cell Reports Medicine] Researchers assessed plasma and liver from 266 obese individuals spanning the metabolic-associated steatotic liver disease spectrum. Ninety-six human livers were precision-cut, and mass spectrometry-based proteomics identified 3,333 proteins in the liver-secretion medium, of which 107 were differentially secreted in metabolic-associated steatohepatitis (MASH) compared with no pathology.
[Cellular and Molecular Life Sciences] The authors elucidated the function and mechanism of latent transforming growth factor beta binding protein 2 (LTBP2) in hepatic stellate cells activation and liver fibrosis.
[Translational Neurodegeneration] The authors summarize the main strategies and techniques of current ALS gene therapies based on ALS risk genes, and review recent findings from animal studies and clinical trials.
[Nature Medicine] Researchers reported on a 45-year-old woman with treatment-refractory Jo-1-associated anti-synthetase syndrome, who initially achieved disease remission after CD19-CAR T-cell therapy but then experienced disease relapse after nine months.